Access to Innovative Treatments Act of 2023
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Access to Innovative Treatments Act of 2023 (H.R. 2408) is a health policy bill introduced in the 118th Congress, originating in the House of Representatives. The bill aims to address issues related to access to new medical treatments, although specific provisions and detailed text are not available. The bill was referred to the Subcommittee on Health but ultimately failed or expired without further legislative action as of the latest update in December 2024.
H.R. 2408 sought to improve access to innovative medical treatments but did not advance beyond subcommittee referral and expired without passage.
- The bill focuses on health policy, specifically access to innovative treatments.
- It was introduced in the House during the 118th Congress but lacks publicly available detailed text or summary.
- The latest recorded action was referral to the Subcommittee on Health on December 17, 2024.
- The bill status is marked as failed or expired, indicating no enactment.
['Patients seeking access to new or innovative medical treatments', 'Healthcare providers involved in delivering such treatments', 'Potentially pharmaceutical and biotechnology companies developing innovative therapies']
['Lack of available full text and official summary limits understanding of specific provisions and implementation requirements', 'Without detailed funding or enforcement language, cost implications and oversight mechanisms are unclear', 'Failure to advance beyond subcommittee stage suggests possible legislative or policy challenges']
The bill was introduced in the 118th Congress and referred to the House Subcommittee on Health. It did not progress further and expired, reflecting the legislative process where many bills do not advance to full consideration or passage. The absence of detailed public documentation limits insight into the bill's legislative support or opposition.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Potential increased public and stakeholder interest in access to innovative treatments despite legislative failure', 'Possible influence on future bills addressing similar health access issues', 'Healthcare providers and companies may continue to advocate for policy changes in this area']
The absence of a full bill text and official summary reduces transparency and limits the ability of the public and oversight entities to fully evaluate the bill's provisions and implications. The bill's failure to progress beyond subcommittee referral highlights the importance of tracking legislative movement to understand policy development and potential gaps in access to innovative treatments.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.